Aripiprazole treatment for patients with schizophrenia

From acute treatment to maintenance treatment

Min Hyeon Park, Changsu Han, Chi Un Pae, Soo Jung Lee, Ashwin A. Patkar, Praksh S. Masand, Wolfgang W. Fleischhacker

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The most current treatment guidelines for schizophrenia recommend more than 1 year of maintenance therapy after the first psychotic episode, and more than 5 years of maintenance therapy after multiple psychotic episodes. Approximately two-thirds of such patients are known to relapse within 1 year and almost 90% of such patients may recur within 2 years. To maintain adequate consistent treatment, balancing the efficacy and safety/tolerability should be one of the most important clinical issues. In this respect, aripiprazole appears to be a good treatment option owing to its comparable efficacy, favorable safety and tolerability profile, including low incidence of parkinsonian symptoms, lack of prolactin elevation, decreased adrenergic and anticholinergic side effects, less weight gain and low incidence of metabolic syndrome. Hence this article aims to summarize the currently available clinical trial data of aripiprazole published from a number of large-scale randomized controlled studies, including a newer formulation of intramuscular injection as well as a once-monthly intramuscular depot formulation, to update knowledge of treatment options in patients with schizophrenia.

Original languageEnglish
Pages (from-to)1541-1552
Number of pages12
JournalExpert Review of Neurotherapeutics
Volume11
Issue number11
DOIs
Publication statusPublished - 2011 Nov 1

Fingerprint

Schizophrenia
Therapeutics
Safety
Intramuscular Injections
Incidence
Cholinergic Antagonists
Prolactin
Adrenergic Agents
Weight Gain
Aripiprazole
Clinical Trials
Guidelines
Recurrence

Keywords

  • acute treatment
  • aripiprazole
  • maintenance treatment
  • schizophrenia

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Park, M. H., Han, C., Pae, C. U., Lee, S. J., Patkar, A. A., Masand, P. S., & Fleischhacker, W. W. (2011). Aripiprazole treatment for patients with schizophrenia: From acute treatment to maintenance treatment. Expert Review of Neurotherapeutics, 11(11), 1541-1552. https://doi.org/10.1586/ern.11.151

Aripiprazole treatment for patients with schizophrenia : From acute treatment to maintenance treatment. / Park, Min Hyeon; Han, Changsu; Pae, Chi Un; Lee, Soo Jung; Patkar, Ashwin A.; Masand, Praksh S.; Fleischhacker, Wolfgang W.

In: Expert Review of Neurotherapeutics, Vol. 11, No. 11, 01.11.2011, p. 1541-1552.

Research output: Contribution to journalArticle

Park, Min Hyeon ; Han, Changsu ; Pae, Chi Un ; Lee, Soo Jung ; Patkar, Ashwin A. ; Masand, Praksh S. ; Fleischhacker, Wolfgang W. / Aripiprazole treatment for patients with schizophrenia : From acute treatment to maintenance treatment. In: Expert Review of Neurotherapeutics. 2011 ; Vol. 11, No. 11. pp. 1541-1552.
@article{2a199f3bf9a7404fba62034243b54b2f,
title = "Aripiprazole treatment for patients with schizophrenia: From acute treatment to maintenance treatment",
abstract = "The most current treatment guidelines for schizophrenia recommend more than 1 year of maintenance therapy after the first psychotic episode, and more than 5 years of maintenance therapy after multiple psychotic episodes. Approximately two-thirds of such patients are known to relapse within 1 year and almost 90{\%} of such patients may recur within 2 years. To maintain adequate consistent treatment, balancing the efficacy and safety/tolerability should be one of the most important clinical issues. In this respect, aripiprazole appears to be a good treatment option owing to its comparable efficacy, favorable safety and tolerability profile, including low incidence of parkinsonian symptoms, lack of prolactin elevation, decreased adrenergic and anticholinergic side effects, less weight gain and low incidence of metabolic syndrome. Hence this article aims to summarize the currently available clinical trial data of aripiprazole published from a number of large-scale randomized controlled studies, including a newer formulation of intramuscular injection as well as a once-monthly intramuscular depot formulation, to update knowledge of treatment options in patients with schizophrenia.",
keywords = "acute treatment, aripiprazole, maintenance treatment, schizophrenia",
author = "Park, {Min Hyeon} and Changsu Han and Pae, {Chi Un} and Lee, {Soo Jung} and Patkar, {Ashwin A.} and Masand, {Praksh S.} and Fleischhacker, {Wolfgang W.}",
year = "2011",
month = "11",
day = "1",
doi = "10.1586/ern.11.151",
language = "English",
volume = "11",
pages = "1541--1552",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - Aripiprazole treatment for patients with schizophrenia

T2 - From acute treatment to maintenance treatment

AU - Park, Min Hyeon

AU - Han, Changsu

AU - Pae, Chi Un

AU - Lee, Soo Jung

AU - Patkar, Ashwin A.

AU - Masand, Praksh S.

AU - Fleischhacker, Wolfgang W.

PY - 2011/11/1

Y1 - 2011/11/1

N2 - The most current treatment guidelines for schizophrenia recommend more than 1 year of maintenance therapy after the first psychotic episode, and more than 5 years of maintenance therapy after multiple psychotic episodes. Approximately two-thirds of such patients are known to relapse within 1 year and almost 90% of such patients may recur within 2 years. To maintain adequate consistent treatment, balancing the efficacy and safety/tolerability should be one of the most important clinical issues. In this respect, aripiprazole appears to be a good treatment option owing to its comparable efficacy, favorable safety and tolerability profile, including low incidence of parkinsonian symptoms, lack of prolactin elevation, decreased adrenergic and anticholinergic side effects, less weight gain and low incidence of metabolic syndrome. Hence this article aims to summarize the currently available clinical trial data of aripiprazole published from a number of large-scale randomized controlled studies, including a newer formulation of intramuscular injection as well as a once-monthly intramuscular depot formulation, to update knowledge of treatment options in patients with schizophrenia.

AB - The most current treatment guidelines for schizophrenia recommend more than 1 year of maintenance therapy after the first psychotic episode, and more than 5 years of maintenance therapy after multiple psychotic episodes. Approximately two-thirds of such patients are known to relapse within 1 year and almost 90% of such patients may recur within 2 years. To maintain adequate consistent treatment, balancing the efficacy and safety/tolerability should be one of the most important clinical issues. In this respect, aripiprazole appears to be a good treatment option owing to its comparable efficacy, favorable safety and tolerability profile, including low incidence of parkinsonian symptoms, lack of prolactin elevation, decreased adrenergic and anticholinergic side effects, less weight gain and low incidence of metabolic syndrome. Hence this article aims to summarize the currently available clinical trial data of aripiprazole published from a number of large-scale randomized controlled studies, including a newer formulation of intramuscular injection as well as a once-monthly intramuscular depot formulation, to update knowledge of treatment options in patients with schizophrenia.

KW - acute treatment

KW - aripiprazole

KW - maintenance treatment

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=80054914101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054914101&partnerID=8YFLogxK

U2 - 10.1586/ern.11.151

DO - 10.1586/ern.11.151

M3 - Article

VL - 11

SP - 1541

EP - 1552

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 11

ER -